Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
JN JNJ JOHNSON & JOHNSON FY ended Feb 06, 2026 | $265.34 | $639.44B | $696.85B | $94.19B | $37.95B | $26.80B | 24.06x | 6.79x | 17.50x |
AB ABT ABBOTT LABORATORIES FY ended Jan 31, 2026 | $112.47 | $195.90B | $209.85B | $44.33B | $12.22B | $6.52B | 30.23x | 4.42x | 16.44x |
MD MDT Medtronic plc FY ended Jun 12, 2026 | $91.10 | $116.61B | $133.71B | $36.36B | $9.78B | $4.80B | 24.42x | 3.21x | 12.67x |
BD BDX BECTON DICKINSON & CO FY ended Oct 31, 2025 | $189.91 | $51.73B | $72.88B | $21.84B | $4.81B | $1.68B | 32.63x | 2.37x | 13.29x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 13.74x | 4/4 | $58.36B | $165.18 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 4.20x | 4/4 | $42.23B | $119.54 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 27.84x | 4/4 | $79.50B | $225.03 | Included in the active peer mix. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
JN JNJ JOHNSON & JOHNSON FY ended Feb 06, 2026 | $265.34 | $639.44B | $696.85B | $94.19B | $37.95B | $26.80B | 24.06x | 6.79x | 17.50x |
AB ABT ABBOTT LABORATORIES FY ended Jan 31, 2026 | $112.47 | $195.90B | $209.85B | $44.33B | $12.22B | $6.52B | 30.23x | 4.42x | 16.44x |
MD MDT Medtronic plc FY ended Jun 12, 2026 | $91.10 | $116.61B | $133.71B | $36.36B | $9.78B | $4.80B | 24.42x | 3.21x | 12.67x |
BD BDX BECTON DICKINSON & CO FY ended Oct 31, 2025 | $189.91 | $51.73B | $72.88B | $21.84B | $4.81B | $1.68B | 32.63x | 2.37x | 13.29x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 13.74x | 4/4 | $58.36B | $165.18 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 4.20x | 4/4 | $42.23B | $119.54 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 27.84x | 4/4 | $79.50B | $225.03 | Included in the active peer mix. |